Soligenix Management

Management criteria checks 4/4

Soligenix's CEO is Christopher Schaber, appointed in Aug 2006, has a tenure of 17.58 years. total yearly compensation is $700.49K, comprised of 74.2% salary and 25.8% bonuses, including company stock and options. directly owns 0.058% of the company’s shares, worth $3.72K. The average tenure of the management team and the board of directors is 9.7 years and 14.7 years respectively.

Key information

Christopher Schaber

Chief executive officer

US$700.5k

Total compensation

CEO salary percentage74.2%
CEO tenure17.6yrs
CEO ownership0.06%
Management average tenure9.7yrs
Board average tenure14.7yrs

Recent management updates

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%

Dec 22

Soligenix announces $20M strategic convertible debt financing agreement

Dec 16

Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Nov 20
Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

CEO Compensation Analysis

How has Christopher Schaber's remuneration changed compared to Soligenix's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$700kUS$519k

-US$6m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$711kUS$499k

-US$14m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$687kUS$485k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$944kUS$475k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$688kUS$466k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$619kUS$453k

-US$9m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$674kUS$444k

-US$7m

Compensation vs Market: Christopher's total compensation ($USD700.49K) is about average for companies of similar size in the US market ($USD662.84K).

Compensation vs Earnings: Christopher's compensation has been consistent with company performance over the past year.


CEO

Christopher Schaber (57 yo)

17.6yrs

Tenure

US$700,485

Compensation

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman of the Board of Directors17.6yrsUS$700.49k0.058%
$ 3.7k
Jonathan Guarino
Senior VP4.5yrsUS$354.69k0.0071%
$ 453.9
Oreola Donini
Senior VP & Chief Scientific Officer9.3yrsUS$387.59k0%
$ 0
Richard Straube
Senior VP & Chief Medical Officer10.2yrsUS$249.94k0.0052%
$ 330.6

9.7yrs

Average Tenure

54yo

Average Age

Experienced Management: SNGX's management team is seasoned and experienced (9.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Schaber
Chairman of the Board of Directors17.6yrsUS$700.49k0.058%
$ 3.7k
Jerome Zeldis
Independent Director12.8yrsUS$72.50k0.015%
$ 945.0
Gregory Lapointe
Independent Director15yrsUS$77.50k0.0047%
$ 304.3
Robert Rubin
Independent Director14.4yrsUS$80.00k0.0028%
$ 181.0
Dorothy Mary Keefe
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Jeffrey Hyams
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
James Markowitz
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Joel Rosh
Member of Pediatric Crohn's Disease Medical Advisory Boardno datano datano data
Alain Rook
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Mark Schubert
Member of Oral Mucositis Medical Advisory Boardno datano datano data
Youn Kim
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data
Gary Wood
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno datano datano data

14.7yrs

Average Tenure

68.5yo

Average Age

Experienced Board: SNGX's board of directors are seasoned and experienced ( 14.7 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.